Monator – Drug monitoring of Tysabri in MS

Ensuring continuity of care for patients living with Multiple Sclerosis (MS) during the COVID-19 pandemic is critical for providers and patients.

The impact of the pandemic on physical access to treatment and precautions that need to be taken by patient and provider are significant.

As stated by the National Multiple Sclerosis Society, “MS itself does not increase the risk of getting COVID-19, however, certain factors associated with your MS may increase your risk for complications:

  • Chronic medical conditions, such as lung disease, heart disease, diabetes or cancer
  • Significantly restricted mobility, such as needing to spend most of your day seated or in bed
  • Age 60 or older
  • Possibly taking certain disease modifying therapies that deplete immune system cells”

moNATor® from Aegirbio measures the amount of Tysabri in an MS patient’s blood. This information may help optimize treatment intervals, reducing the risk of exposure to COVID-19 and also potentially reducing the risk of progressive multifocal leukoencephalopathy (PML).

For more information on how to order moNATor® contact us on info@aegirbio.com

For Healthcare professionals

moNATor® is the first dose-monitoring laboratory test that that provides you with data that may aid in making clinical decisions when using Natalizumab (Tysabri).

With a simple blood draw, you can measure natalizumab levels in your patients at regular intervals to inform treatment decisions.

To learn more, download the moNATor healthcare flyer and contact us at info@aegirbio.com today.

For Patients

If you’re impacted by multiple sclerosis (MS) you may know that using Tysabri (natalizumab), while clinically proven to be beneficial, comes with risks.

moNATor® from Aegirbio was designed to measure the amount of Tysabri in your blood. This information may help optimize your treatment intervals, potentially reducing PML risk.

A simple blood test (done right within your regular infusion routine) can provide data on which Tysabri (natalizumab) treatment interval may be appropriate for YOU.

Ask your doctor for more information.

Technology

Veritope

The Veritope Platform is a proprietary reagent platform based on peptide mimetopes that detect a given biologic drug by mimicking the natural ligand target, including cell membrane bound proteins. 

Veritopes specifically detect the target biologic drug in human samples such as serum and plasma and can be implemented in a variety of applications such as lab-based assays or point-of-care.

MagniaReader

The Magnia Point of Care / Point of Need table top reader uses magnetic technology to allow high sensitivity and accuracy quantitative readouts from disposable test strips.